ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Roche Holding Ag

Roche Holding Ag (0QQ6)

229.20
0.00
( 0.00% )
Updated: 20:00:00

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
229.20
Bid
0.00
Ask
0.00
Volume
30
0.00 Day's Range 0.00
229.20 52 Week Range 229.20
Market Cap
Previous Close
229.20
Open
-
Last Trade
6
@
308
(O)
Last Trade Time
05:35:13
Financial Volume
-
VWAP
-
Average Volume (3m)
3,355
Shares Outstanding
0.00
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
58.72B
Net Profit
11.5B

About Roche Holding Ag

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Basel, Che
Founded
1970
Roche Holding Ag is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0QQ6. The last closing price for Roche was CHF229.20. Over the last year, Roche shares have traded in a share price range of CHF 229.20 to CHF 229.20.

Roche currently has 0 shares outstanding.

0QQ6 Latest News

European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)

European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO) Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO...

Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care

Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care The acquisition of LumiraDx’s Point of Care technology received all required...

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised Group sales were up by 5%1...

New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions

New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye...

Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study

Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study More than 90% of patients had absence of DME after...

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity After four weeks of...

Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes

Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes The Accu-Chek® SmartGuide CGM solution provides 14...

Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)

Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD) The FDA has approved updates to Susvimo, which will be available to US retina specialists...

FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss

FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer SKYSCRAPER-06 evaluating tiragolumab...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
100229.2229.2229.21427229.2DE
400229.2229.2229.21513229.2DE
1200229.2229.2229.23355229.2DE
2600229.2229.2229.25067229.2DE
5200229.2229.2229.25288229.2DE
15600229.2229.2229.25980229.2DE
26000229.2229.2229.24627229.2DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
JWNGJaywing Plc
2.05p
(46.43%)
1.16M
MTROMetro Bank Holdings Plc
54.60p
(35.82%)
8.71M
ECHOEcho Energy Plc
0.0042p
(31.25%)
11.35B
ELEGElectric Guitar Plc
0.875p
(29.63%)
6.72M
STXShield Therapeutics Plc
2.45p
(22.50%)
4.34M
NARFNarf Industries Plc
0.80p
(-27.27%)
12.25M
DESTDestiny Pharma Plc
2.25p
(-23.73%)
666.45k
UKOGUk Oil & Gas Plc
0.0585p
(-23.03%)
2.02B
MSMNMosman Oil And Gas Limited
0.044p
(-21.43%)
747.25M
TUNTungsten West Plc
2.25p
(-18.18%)
406.99k
ECHOEcho Energy Plc
0.0042p
(31.25%)
11.35B
UKOGUk Oil & Gas Plc
0.0585p
(-23.03%)
2.02B
MSMNMosman Oil And Gas Limited
0.044p
(-21.43%)
747.25M
GWMOGreat Western Mining Corporation Plc
0.049p
(2.08%)
319.15M
PREMPremier African Minerals Limited
0.0575p
(-7.26%)
182.7M

Discussion

View Full Feed
Skipperdog11 Skipperdog11 27 seconds ago
can we at least now all agree that a buyback has no place in the on-going actions of this company. Ramp ups in row, multi-front legal battles, rapidly declining domestic revenue, challenging supply chain obligations, etc. .....................
AMRN
zab zab 37 seconds ago
Why did trump and the Republicans vote against that border security bill.?
Thomas@yahoo Thomas@yahoo 1 minute ago
https://www.jdsupra.com/legalnews/congress-advances-cannabis-and-hemp-5541083/
CVSI
Here Today Here Today 2 minutes ago
Insane the mismanagement of this company!!!
RNAZ
chereb19 chereb19 2 minutes ago
https://programme.conventus.de/en/ecmp-dgmp-2024/program/program-points/ec11ad31-5d37-4696-8025-e610b31d021e

https://investorshub.advfn.com/uimage/uploads/2024/7/31/fkskckrim.JPG

https://investorshub.advfn.com/uimage/uploads/2024/7/31/h[nwbkrim1.JPG
RDGL
rosemountbomber rosemountbomber 2 minutes ago
Totally agree although that Caremark loss is such a giant and sudden loss of revenue, that unfortunately the EU revenue uptick is too slow to cover at this stage. In a year or two it will hopefully but sadly in these next few months it is too much to hope for based on what we are seeing.
AMRN
tradernewstip tradernewstip 2 minutes ago
$ADMQ Big things coming next month! stay tuned!!!

Explore what our team at FW Promo is all about! From screen printing to embroidery and custom promotional products, we've got all your needs covered. Proudly part of ADM Endeavors, Inc. #stocks #StocksInFocus #StocksToWatch #investing
ADMQ
RickNagra RickNagra 2 minutes ago
Oh wow.
DBMM
m0n m0n 3 minutes ago
I FU S didn’t help create the legislation in a state house bill LoL

Get F’ing Real!


IFUS
prototype_101 prototype_101 3 minutes ago
NLM is NOWHERE close to LWLG!! All anyone has to do is look at the "Spider Chart" on Slide 13 to see the TRUTH!!!! NLM is the "Competition" (in Polymers) being referred to on this slide!! NLM is literally YEARS behind LWLG in Developments and honestly their "cross linking" approach is inferior and t
LWLG OLED
Here Today Here Today 4 minutes ago
Why hasn’t any of the 4 current selected sites started recruiting? What are they waiting for since 7/03/24????
RNAZ
Here Today Here Today 4 minutes ago
Management of this company has been criminal. Starting with advertising on CNBC during Mad Money’s show to suck in the naive retail investors so as to take another Reverse Split hit!
RNAZ
Here Today Here Today 5 minutes ago
The pump is over.
RNAZ
Hoskuld Hoskuld 6 minutes ago
Good find, thanks.
AVXL
JRoon71 JRoon71 6 minutes ago
Cash was essentially flat, so they are still staying cash-neutral. It would be great if they could start clearing enough revenue in EU to offset the projected losses from CVS, and avoid any cash drain going forward.
CVS
dave79 dave79 7 minutes ago
JAB- I would concur. I too feel like Delfin is going to have to take some risk and finally pull the trigger here and move forward with the project/ship build etc. Even while they wait for the DOE & Marad, they have to know they will eventually receive re-approval. With their high powered lawyers etc
TGLO
Diamondhands45 Diamondhands45 7 minutes ago
Bro he kills it. GTFO clown
TSLA
snow snow 7 minutes ago
RD "How is that? Is $250 fair value for gold (SIRI) not enough for you?" Strangely a valuation of 9 dollars suits me better than a valuation of 250 dollars. With a valuation of 9 dollars I am able to pay the wealth tax. That is not the case with a valuation of 250 dollars per token as long as I cann
SIRI
surfkast surfkast 7 minutes ago
Can someone provide valid documentation as to why this will run in 2025? (Not GS Hopium please.)
We know of all the issues. So what will change?
Please review the known obstacles. Thanks.

Hi_Lo

Re: Lime Time post# 172240

Tuesday, July 30, 20
GVSI
Midwestrader Midwestrader 7 minutes ago
Yep...BAGHOLDER BOY doubled down on this POS CON JOB and is losing his azzzz. He just knew this CON was going to run again so he took his profits and BOUGHT BIG this time just knowing another run would happen.

Bwahahahahhahaha!!!

Now his shares are virtually worthless
INND
Grouse Hunter Grouse Hunter 8 minutes ago
Honeymoon period. You don’t win anything in July. Still lots of ups and downs to go.
TGLO
tradernewstip tradernewstip 8 minutes ago
$CBDW 1606 Corp is transforming e-commerce with IRchat, a pioneering AI chatbot technology. With the AI market expected to soar to $2.25 trillion by 2030, 1606 Corp. stands at the forefront of technological innovation.

Register HERE for Our Webinar with CEO Austin Lambrecht: https://
CBDW
uranium-pinto-beans uranium-pinto-beans 8 minutes ago
Garmin reports Q2 pro forma EPS $1.58, consensus $1.41
Reports Q2 revenue $1.51B, consensus $1.42B. CEO Cliff Pemble said, "Garmin delivered another impressive quarter of growth in both revenue and operating profit, made possible by an innovative product lineup and the strength of our diversi

Your Recent History

Delayed Upgrade Clock